 Alzheimer's-type dementia, ATD, treatments face several limitations when administered orally, including poor bioavailability and systemic side effects. Intranasal delivery, however, has shown promise as a non-invasive method of delivering drugs directly to the brain through the nose. Lipid-based nanoformulations, such as nanostructured lipid carriers, NLCs, have been studied extensively for this purpose and show great potential for overcoming the challenges associated with other nanoparticles. Despite some successes, there remain many unanswered questions regarding the safety and efficacy of these formulations. Further research is needed to determine which candidate drugs should be pursued for intranasal administration in treating ATD. This article was authored by Raquel Talens Visconde, Jesus Vicente de Julian Ortiz, Ophelia Villabuso, and others.